Oxford, U.K.-based Osler Diagnostics on Monday announced it has raised $85 million in a Series C financing to support advancing its Osler Origin product through regulatory activities and toward market launch.
The Osler Origin is a portable diagnostic platform designed to perform a wide range of tests. The firm said that with its portable lab, it aims to provide lab-quality tests anywhere.
Its lab-in-the-hand technology includes microfluidic sample preparation and electrochemical biosensing, according to Osler's website. The Osler Origin will offer a wide portfolio of diagnostic tests for all major healthcare settings.
The financing round included investment from M&G Investments and existing investors, including Oxford Science Enterprises, Braavos Investment Advisers, and Lansdowne Partners, Osler said.
